Endothelin receptor antagonists for pulmonary arterial hypertension

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Liu, Chao ^a   Chen, Junmin ^b   Gao, Yanqiu ^a   Deng, Bao ^a   Liu, Kunshen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; SILDENAFIL; SITAXSENTAN; ANTIHYPERTENSIVE AGENT; ENDOTHELIN RECEPTOR;

ARTERIAL OXYGEN SATURATION; BORG DYSPNEA SCORE; CARDIAC INDEX; DETERIORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FUNCTIONAL STATUS; HEART OUTPUT; HUMAN; LIVER FAILURE; LIVER TOXICITY; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG VASCULAR RESISTANCE; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SCORING SYSTEM; SIX MINUTE WALK TEST; SYSTEMATIC REVIEW; DRUG ANTAGONISM; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, PULMONARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN;

EID: 84875513420     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004434.pub5     Document Type: Review

References (123)

1. US Food and Drug Administration. Center for drug evaluation and research. Letairis (Ambrisentan) Tablets: Medical Review(s). http://www.fda.gov/cder/foi/nda/2007/022081s000TOC.htm (Accessed March 20, 2008).
2. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al.Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-9.
3. US Food and Drug Administration. Center for drug evaluation and research. Letairis (Ambrisentan) Tablets: Medical Review(s). http://www.fda.gov/cder/foi/nda/2007/022081s000TOC.htm (Accessed March 20, 2008).
4. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al.Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010-9.
5. Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza RL, Castro O, et al.Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology 2010;149(3):426-35.
6. US Food and Drug Administration. Center for drug evaluation and research.Tracleer (Bosentan) Tablets: Medical Review(s). http://www.fda.gov/cder/foi/nda/2001/21-290_Tracleer.htm Vol. Accessed March 20, 2008.
7. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A. Bosentan therapy for pulmonary arterial hypertension. The New England Journal of Medicine 2002;346(12):896-03.
8. US Food and Drug Administration. Center for drug evaluation and research.Tracleer (Bosentan) Tablets: Medical Review(s). http://www.fda.gov/cder/foi/nda/2001/21-290_Tracleer.htm (Accessed March 20, 2008).
9. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al.Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. The European Respiratory Journal 2004;24(3):353-9.
10. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al.Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114(1):48-54.
11. Badesch DB, Bodin F, Channick RN, Frost A, Rainisio M, Robbins IM, et al.complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. Current Therapeutic Research, Clinical & Experimental 2002;63(4):227-46.
12. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288):1119-23.
13. Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al.Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371(9630):2093-100.
14. Galiè N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al.Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology 2003;41(8):1380-6.
15. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al.Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. American Journal of Respiratory & Critical Care Medicine 2005;171(11):1292-7.
16. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (Accessed March 22, 2008).
17. Therapeutic Goods Administration (TGA), Australia. Public Summary Documents by Product: Thelin. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-sitaxentan-sodium-july07 (Accessed April 25, 2008).
18. Barst RJ, Langleben D, Frost E, Horn EM, Oudiz R, Shapiro S, et al.Sitaxsentan therapy for pulmonary arterial hypertension. Amercian Journal of Respiratory and Critical Care Medicine 2004;169:441-7.
19. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf Accessed March 22, 2008.
20. Barst RJ, Langleben D, Frost E, Horn EM, Oudiz R, Shapiro S, et al.Sitaxsentan therapy for pulmonary arterial hypertension. Amercian Journal of Respiratory and Critical Care Medicine 2004;169:441-7.
21. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (Accessed March 22, 2008).
22. Barst RJ, Langleben D, Frost E, Horn EM, Oudiz R, Shapiro S, et al.Sitaxsentan therapy for pulmonary arterial hypertension. Amercian Journal of Respiratory and Critical Care Medicine 2004;169:441-7.
23. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (Accessed March 22, 2008).
24. Therapeutic Goods Administration (TGA), Australia. Public Summary Documents by Product: Thelin. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-sitaxentan-sodium-july07 (Accessed April 25, 2008).
25. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al.Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Journal of the American College of Cardiology 2006;47(10):2049-56.
26. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (Accessed March 22, 2008).
27. Therapeutic Goods Administration (TGA), Australia. Public Summary Documents by Product: Thelin. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-sitaxentan-sodium-july07 (Accessed April 25, 2008).
28. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al.Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Journal of the American College of Cardiology 2006;47(10):2049-56.
29. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (Accessed March 22, 2008).
30. Therapeutic Goods Administration (TGA), Australia. Public Summary Documents by Product: Thelin. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-sitaxentan-sodium-july07 (Accessed April 25, 2008).
31. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, et al.Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. Journal of the American College of Cardiology 2006;47(10):2049-56.
32. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (Accessed March 22, 2008).
33. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (Accessed March 22, 2008).
34. European Medicines Agency. EPARs for authorised medicinal products for human use: Thelin. European Public Assessment Report. www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6.pdf (Accessed March 22, 2008).
35. Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza RL, Castro O, et al.Exercise capacity and haemodynamics inpatients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology 2010;149(3):426-35.
36. Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, et al.Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. Journal of Heart & Lung Transplantation 2011;30(6):632-43.
37. Benza RL, Mehta S, Keogh A, Lawrence EC, Oudiz RJ, Barst RJ. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2007;26(1):63-9.
38. Bose N, Bena JF, Trunick CM, Bork DJ, Krishnan G, Petrich J, et al.Evaluation of the effect of ambrisentan on digital microvascular flow in patients with systemic sclerosis using laser Doppler perfusion imaging. Arthritis and Rheumatism 2009;62(Suppl 10):574.
39. Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma. http://clinicaltrials.gov/ct2/show/NCT00070590.
40. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. European Journal of Clinical Pharmacology 2008;64(1):43-50.
41. Coyne TC, Garces PC, Kramer W. No clinical interaction between sitaxsentan and sildenafil [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[A57] [Poster: K70].
42. Denault A. Multicentered trial of tezosentan in cardiac surgery. Canadian Journal of Anesthesia 2010;57(Supplement 1):S227.
43. Dhaun N, Johnston NR, Goddard J, Webb DJ. Chronic selective endothelin a receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease. Hypertension 2011;58(2):e11-2.
44. Faoro V, Boldingh S, Moreels M, Martinez S, Lamotte M, Unger P, et al.Bosentan decreases pulmonary vascular resistance and improves exercise capacity in acute hypoxia. Chest 2009;135(5):1215-22.
45. Faoro V, Huez S, Boldingh S, Moreels M, Martinez S, Bastin R, et al.Bosentan improves exercise capacity in acute hypoxic subjects. Acta Cardiologica 2009;64(4):112.
46. Frey R, Muck W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: An ascending-dose study in healthy male volunteers. Journal of Clinical Pharmacology 2008;48(8):926-34.
47. Galiè N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al.Ambrisentan therapy for pulmonary arterial hypertension. Journal of the American College of Cardiology. 2005;46(3):529-35.
48. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al.Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894-903.
49. Galiè N, Naeije R, Burgess G, Dilleen M. 3-year survival of patients treated with sitaxentan sodium (Thelin) for pulmonary arterial hypertension. European Heart Journal 2009;Abstract Supplement:262.
50. Galiè N, Badesch D, Fleming T, Simonneau G, Rubin L, Ewert R, et al.Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH): Results from a phase II study. European Heart Journal 2010;Conference Publication:(Abstract Supplement):22.
51. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock A, Barst RJ, et al.Long term use of imatinib In patients with severe pulmonary arterial hypertension [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A2513.
52. Gillies HC, Wang X, Staehr P, Zack J. PAH therapy In HIV: Lack of drug-drug interaction between ambrisentan and ritonavir [Lack of drug-drug interaction between ambrisentan and ritonavir]. American Journal of Respiratory and Critical Care Medicine 2011; Vol. 183:A5913.
53. Givertz MM, Colucci WS, LeJemtel TH, Gottlieb SS, Hare JM, Slawsky MT, et al.Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000;101(25):2922-7.
54. Gomberg-Maitland M, McLaughlin V, Gulati M, Rich S, Arbor A. Efficacy and safety of sildenafil and atorvastatin added to bosentan as therapy for pulmonary arterial hypertension [Abstract]. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005:[A57] [Poster: K18].
55. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. Journal of Clinical Pharmacology 2010;50(7):829-34.
56. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al.Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. The European Respiratory Journal 2006;28(4):691-4.
57. Huez S, Faoro V, Moreels M, Bastin R, Retailleau K, Lamotte M, et al.Role of pulmonary hypertension and right ventricular dysfunction in aerobic exercise capacity limitation in normal volunteers at high altitude. Acta Cardiologica 2009;64(1):114.
58. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial. European Heart Journal 2010;31(9):1124-31.
59. Jais X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al.Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. Journal of the American College of Cardiology 2008;52(25):2127-34.
60. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?. International Journal of Cardiology 2002;85(2-3):195-7.
61. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, et al.Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology 2008;109(4):273-80.
62. Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, et al.Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study. Cardiology 2008;109(4):273-80.
63. Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Molecular Cancer 2010;9:69.
64. King TE, Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al.BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis [King TE Jr Behr J]. American Journal of Respiratory & Critical Care Medicine 2008;177(1):75-81.
65. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, et al.Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346(8977):732-6.
66. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al.Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis and Rheumatism 2004;50(12):3985-93.
67. Lee TM, Chen CC, Shen HN, Chang NC. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clinical science 2009;116(6):497-505.
68. McLaughlin VV, Gaine SP, Barst RJ, Oudiz RJ, Bourge RC, Frost A, et al.Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension. Journal of Cardiovascular Pharmacology 2003;41(2):293-9.
69. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al.Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. American Journal of Respiratory & Critical Care Medicine 2006; Vol. 174, issue 11:1257-63.
70. McLaughlin VV, Benza R L, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al.Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. Journal of the American College of Cardiology 2010;55(18):1915-22.
71. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al.Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006;114(14):1482-9.
72. Modesti PA, Vanni S, Morabito M, Modesti A, Marchetta M, Gamberi T, et al.Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. Circulation 2006; Vol. 114, issue 13:1410-6.
73. Naeije R, Huez S, Lamotte M, Retailleau K, Neupane S, Abramowicz D, et al.Pulmonary artery pressure limits exercise capacity at high altitude. European Respiratory Journal 2010;36(5):1049-55.
74. Nakahara N, Wakamatsu A, Shimamura R, Nohda S, Miki S, Hirama T. Pharmacokinetics of ambrisentan, a novel drug for treatment of Pulmonary Arterial Hypertension (PAH), in Japanese subjects. Japanese Journal of Clinical Pharmacology and Therapeutics 2010;41(6):301-8.
75. Oudiz RJ. Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension. Chest 2007;132(4):474a.
76. Oudiz RJ, Galiè N, Olschewski H, Torres F, Frost A, Ghofrani HA, et al.Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. Journal of the American College of Cardiology 2009;54(21):1971-81.
77. Efficacy and safety of tral bosentan on healing/prevention of digital (finger) ulcers in scleroderma patients. http://clinicaltrials.gov/ct2/show/NCT00077584.
78. Reesink HJ, Surie S, Kloek JJ, Tan HL, Tepaske R, Fedullo PF, et al.Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Journal of Thoracic & Cardiovascular Surgery 2010;139(1):85-91.
79. Robbins IM, Kawut SM, Yung D, Reilly MP, Lloyd W, Cunningham G, et al.A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. European Respiratory Journal 2006;27(3):578-84.
80. Seheult RD, Ruh K, Foster GP, Anholm JD. Prophylactic bosentan does not improve exercise capacity or lower pulmonary artery systolic pressure at high altitude. Respiratory Physiology & Neurobiology 2009;165(2-3):123-30.
81. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, et al.Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis and Rheumatism 2010;62(7):2101-8.
82. Shenoy PD, Agarwal V. Tadalafil: A new role in Raynaud's phenomenon?. International Journal of Clinical Rheumatology. 2011; Vol. 6, issue 2:115-7.
83. Simonneau G, Lang I, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, et al.Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study In pulmonary arterial hypertension (PAH). American Journal of Respiratory and Critical Care Medicine 2010;181(Meeting Abstracts):A2515.
84. Spence R, Mandagere A, Dufton C, Venitz J. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. Journal of Clinical Pharmacology 2008;48(12):1451-9.
85. Spence R, Mandagere A, Harrison B, Dufton C, Boinpally R. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. Journal of Pharmaceutical Sciences 2009;98(12):4962-74.
86. Stavros F, Kramer WG, Wilkins MR. The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. British Journal of Clinical Pharmacology 2010;69(1):23-6.
87. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, et al.A randomised, controlled trial of bosentan in severe COPD. European Respiratory Journal 2008;32(3):619-28.
88. Worthington A, Collins N, Haddad R. Safety and feasibility of inhaled iloprost on exercise capacity in patients with pulmonary arterial hypertension. Heart Lung and Circulation 2010;19(2):1.
89. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips D L, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. Journal of Clinical Pharmacology 2008;48(5):610-8.
90. Palazzini M, Leci E, Bachetti C, Sgro F, Mazzanti G, Beciani E, et al.A randomized open label study comparing bosentan or sildenafil first-line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). European Heart Journal 2010;31 ( Abstract Supplement ):629-630.
91. Altman DG, Bland JM. Statistics Notes: Interaction revisited: the difference between two estimates. BMJ 2003;326(7382):219.
92. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121(18):2045-66.
93. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Annals of Internal Medicine 2000;132(6):425-34.
94. Badesch DB, the Aries Study Group. Ambrisentan therapy for pulmonary arterial hypertension: a comparison by pah etiology. Chest 2007;132(4):488-9.
95. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. The New England Journal of Medicine 1996;334(5):296-302.
96. Chen Y, Jowett S, Barton P, Malottki K, Hyde C, Gibbs S, et al.Clinical and cost effectiveness of treatments for pulmonary arterial hypertension (PAH) within their licensed indications [updated 21/02/2008]. West Midlands Health Technology Assessment Collaboration 2008.
97. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Annals of the Rheumatic Diseases 2006;65(10):1336-40.
98. Filep JG, Fournier A, Foldes-Filep E. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: involvement of ETA and ETB receptors. British Journal of Pharmacology 1995;115(2):227-36.
99. Fuster V, Steele PM, Edwards ED, Gersh DJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 1984;70(4):580-7.
100. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al.Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine 2005;353:2148-57.
101. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al.Guidelines for the diagnosis and treatment of pulmonary hypertension. European Respiratory Journal 2009;34(6):1219-63.
102. Gater PR, Wasserman MA, Renzetti LM. Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea. European Journal of Pharmacology 1996;304(1-3):123-8.
103. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, et al.Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New England Journal of Medicine 1993;328:1732-9.
104. Hasuda T, Satoh T, Shimouchi A, Sakamaki F, Kyotani S, Matsumoto T. Improvement in exercise capacity with nitric oxide inhalation in patients with precapillary pulmonary hypertension. Circulation 2000;101(17):2066-70.
105. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. European Respiratory Journal 2007;30(2):338-44.
106. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovascular Research 1993;27:2125-9.
107. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, et al.Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. Experimental Lung Research 2000;26(4):287-301.
108. Liu C, Liu K, Ji Z, Liu G. Treatments for pulmonary arterial hypertension. Respiratory Medicine 2006;100(5):765-74.
109. Mansoor AM, Honda M, Saida K, Ishinaga Y, Kuramochi T, Maeda A, et al.Endothelin induced collagen remodeling in experimental pulmonary hypertension. Biochemical and Biophysical Research Communications 1995;215(3):981-6.
110. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al.Survival with first-line bosentan in patients with primary pulmonary hypertension. European Respiratory Journal 2005;25(2):244-9.
111. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al.Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine 2000;161:487-92.
112. Types of Pulmonary Hypertension. website: http://www.nhlbi.nih.gov/health/health-topics/topics/pah/types.html accessed 15/11/2011.
113. Paramothayan NS, Lasserson TJ, Wells AU, Walters EH. Prostacyclin for pulmonary hypertension in adults. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002994.pub2]
114. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. The American Review of Respiratory Disease 1986;134:342-6.
115. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. The New England Journal of Medicine 1992;327(2):76-81.
116. Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schultheiss HP. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120(5):1562-9.
117. Seibold J, Badesch D, Galiè N, Langleben D, Naeije R, Simonneau G, et al.Sitaxsentan, a selective endothelin-a receptor antagonist, improves exercise capacity in pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD). Chest 2005; Vol. 128, issue 4:219S.
118. Sitbon O, Humbert M, Jagot JL, Taravella O, Fartoukh M, Parent F, et al.Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. The European Respiratory Journal 1998;12:265-70.
119. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al.Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. Journal of the American College of Cardiology 2002;40(4):780-8.
120. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. American Journal of Respiratory Cell and Molecular Biology 2001;25:104-10.
121. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004434.pub2]
122. Liu C, Chen J. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004434.pub3]
123. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD004434.pub4]